LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.